www.anesthesia-analgesia.org aNesthesia & aNalgesia less sensitive to modulation by the IV anesthetic etomidate and by the inhaled drug enflurane. 8, 9 Its impact on nonimmobilizers remains unknown.
We combined these 2 approaches and tested whether the nonimmobilizer 1,2-dichlorohexafluorocyclobutane (F6, also referred to in the literature as 2N) modulates α5-containing receptors and whether the β3(N265M) mutation affects that modulation. We chose the α5β3γ2L subunit combination because the β3 subunit is highly colocalized with the α5 subunit in the dendritic layers of the hippocampus, 10 the β3 subunit has been linked to memory impairment by isoflurane, 11 and several in vivo studies have shown that α5-containing receptors influence hippocampus-dependent learning, [12] [13] [14] [15] possibly by modulating the threshold for induction of long-term enhancement. 16 We found that F6, at concentrations ranging from 4 to 16 μM, 17 did indeed enhance α5β3γ2L receptors activated by a low concentration of GABA in a concentration-dependent manner and that the β3(N265M) mutation prevented this enhancement. However, unlike conventional anesthetics, which typically prolong current decay, F6 did not alter deactivation of α5β3γ2L receptors after brief highconcentration pulses of GABA. We conclude that there are common structural requirements, but different kinetic mechanisms, for the enhancing effects of the nonimmobilizer F6 and volatile anesthetics and that enhancement of specific types of GABA A R-mediated inhibition may underlie their amnestic effects.
METHODS Cell Culture and Receptor Expression
Cell culture materials were purchased from Invitrogen (Carlsbad, CA) unless stated otherwise. Transformed human embryonic kidney 293 cells purchased from American Type Culture Collection (Manassas, VA) were cultured under standard conditions in minimal essential medium with l-glutamine supplemented with minimal essential medium amino acid solution (0.1 mM), sodium pyruvate (1 mM), 1% streptomycin, and 10% fetal bovine serum on 12-mm glass coverslips in 60 × 15-mm dishes. Cells were transiently transfected with α5β3 (1:1), α5β3γ2L (1:1:5), α5β3(N265M)γ2L (1:1:5), or α1β2γ2L (1:1:5) subunits individually inserted in the mammalian expression vector pCEP4 (Invitrogen) and enhanced green fluorescence protein using Lipofectamine 2000 (Invitrogen). After incubating for 6 hours, the culture medium was replaced with supplemented minimal essential medium. Cells were used for electrophysiologic recordings 24 to 48 hours after transfection.
Electrophysiologic Recordings
Coverslips with transfected cells were transferred to a culture dish filled with HEPES-buffered extracellular solution containing (mM): 130 NaCl, 3.1 KCl, 10.9 Na-HEPES, 1.44 MgCl 2 , and 2.17 CaCl 2 , pH = 7.3. Recording pipettes were filled with (mM): 140 CsCl, 10 Na-HEPES, 10 EGTA, and 2 MgATP. For concentration-response experiments with F6, the extracellular solution contained (mM): NaCl 145, KCl 5, MgCl 2 1, CaCl 2 1.8, and HEPES 10, pH 7.4; and recording pipettes were filled with (mM): 130 KCl, 10 Na-HEPES, 1 MgCl 2 , 5 EGTA, and 5 MgATP.
Electrophysiologic recordings were performed on the stage of a Nikon inverted microscope (Nikon Instruments Inc., Tokyo, Japan) with Hoffman-modulated optics. Glass pipettes were prepared from borosilicate glass (Warner Instruments, Hamden, CT, or Garner Glass Company, Claremont, CA) with a multistage puller (Sutter Instruments, Novato, CA) and fire polished. Open-tip resistances were typically 2 to 5 MΩ. Cells were visualized using a mercury arc lamp and an enhanced green fluorescence protein filter set. Data were acquired using equipment from Axon Instruments (now a division of Molecular Devices, Sunnyvale, CA). Currents were recorded with the whole-cell configuration of the patch clamp technique using an Axopatch 200B amplifier, sampled at 10 kHz (Digidata 1200 AD converter), filtered at 1 kHz (−3 dB, four-pole Bessel), and stored on an IBMcompatible computer running pCLAMP 9 software.
Solution Application
Extracellular saline and test solutions containing GABA (Sigma, St. Louis, MO) and/or F6 (Lancaster Synthesis Inc., Pelham, NH) were transiently applied to fluorescing whole cells lifted from the coverslip and placed before flowing streams of extracellular solution using 3 different methods. (1) For rapid (~3 ms) solution exchanges among limited numbers of solutions, we used a gravity-fed 2-barrel theta application pipette connected to solution reservoirs using polyimide and Teflon™ (DuPont, Wilmington, DE) tubing and mounted to a stacked piezoelectric translator (Physik Instrumente, Irvine, CA); (2) for slower (~30 ms) solution exchanges among larger numbers of nonvolatile solutions, we used a 16-channel Dynaflow pressurized microfluidic chip (DF-16, Cellectricon, Gaithersburg, MD) with open reservoirs; and (3) for solution exchanges (~30 ms) among larger numbers of solutions that included the volatile compound F6, we used a customfabricated multibarrel application device consisting of Teflon and polyimide tubing connected to closed gravity-fed Teflon solution reservoirs. Test solutions were applied by delivering a filtered (100 Hz, filter model 902 LFP, Frequency Devices, Haverhill, MA) voltage pulse to a high-voltage amplifier (model P-270, Physik Instrumente, Auburn, MA) that drove a translator to which the theta-pipette was mounted (method 1), or using a stepper motor-based microscope translation stage (Corvus, iTK, Dr. Kassen GmbH, Lahnau, Germany) (method 2). Solution exchange rates were estimated using the open-tip junction potential method. 18 Test solution pulses (20 ms or 2 s) were applied at a frequency that prevented accumulation of desensitization, manifested as a decline in peak current amplitudes triggered by saturating concentrations of GABA (1-3 mM) of <5% (data not shown). Concentration-response relationships for α5β3 and α5β3γ2L receptors were constructed by delivering a range of GABA solutions (0.01 μM-3 mM) to single cells using a series of low-volume manually controlled Teflon valves. For α5β3(N265M)γ2L and α1β2γ2L receptors, this was accomplished using the Dynaflow df-16 chip. Deactivation kinetics were assessed by applying 20-ms pulses of 1 mM GABA in the absence or continuous presence of F6. Solutions were prepared as described previously. 17, 19 Briefly, GABA-containing solutions were prepared from a freshly made stock solution. F6-containing solutions were made using F6-saturated air as a "stock" that was added to the experimental solution in gas-tight Chemware Teflon FEP gas sampling bags (North Safety Products, Cranston, RI). The targeted concentrations of F6 ranged from 4 to 16 μM. (An aqueous concentration of 16 μM corresponds to the predicted minimum alveolar concentration [MAC pred ] that would inhibit movement in response to a noxious stimulus if F6 were to obey the Meyer-Overton rule.) 17 Concentrations of F6 were confirmed using a Varian 3700 gas chromatograph (Varian Inc., Walnut Creek, CA) equipped with a flame ionization detector and an 80/100 Poropak Q packed stainless steel column. Measured concentrations were all within ~5% of targeted concentrations.
Data Analysis
Whole-cell currents were analyzed using Origin 6.1 (OriginLab, Northampton, MA) and Excel (Microsoft, Redmond, WA). For generation of concentration-response relationships, peak currents were measured relative to baseline and normalized to the peak current evoked by a saturating concentration (1-3 mM) of GABA and plotted as a function of agonist concentration. Curves were fitted to the equation I = 1 -[1 + ([GABA]/EC 50 ) n ] -1 , where EC 50 is a concentration that yields a half-maximal response and n is the slope coefficient of the sigmoidal fit. Current deactivation triggered by 20-ms pulses of 1 mM GABA was fit by exponential functions beginning shortly after the peak of the response using a Levenberg-Marquardt algorithm. During the fitting process, the goodness of fit was evaluated by the χ 2 value, and adequacy of fit to triexponential functions was judged by eye. To generate a single time constant for comparison between control and F6 deactivation responses, a weighted time constant (τ w ) was calculated according to the equation τ w = (Ʃτ i A i /ƩA i ), where τ i and A i are the time constant and amplitude of the individual exponential components.
Results are presented as mean ±SD or SEM as indicated. The numbers of observations (n) reflect the numbers of cells tested under a specific combination of conditions, such as the receptor subunit combination that was expressed, the concentration of GABA that was used to activate the receptors, and the concentration of F6 that was applied. Because only 1 excised patch was obtained from any individual cell, this number applies to experiments using rapid solution exchange with excised patches as well as slower solution exchange with whole-cell recordings. For the concentration-response studies for F6 using slow solution exchange, each cell was exposed to all concentrations. For other experiments, each cell was exposed to only a single concentration of GABA as indicated, as well as a saturating concentration to permit normalization. The number of observations obtained for each experimental dataset was based on prior experience with similar types of experiments, together with an ongoing qualitative assessment of electrophysiologic responses; once a consistent effect (or lack of effect) under a specific set of conditions was evident, a formal statistical evaluation of the dataset or a representative subset (e.g., 1 specific concentration of GABA in a concentration-response series) was performed. Unpaired t tests were used to test for differences between mean values; statistical significance was evaluated using P < 0.005.
RESULTS

Effects on α5β3 Receptors
Using rapid (~3 ms) solution exchange methods, we tested the effects of F6 on responses of α5β3 receptors activated by saturating concentrations of GABA (1 mM) and on receptors activated by a lower concentration of GABA (1 μM). An example of the response from an individual cell is shown in Figure 1 . Co-application of F6 and 1 mM GABA resulted in the inhibition of peak currents and the emergence of a rebound current after drug washout (Fig. 1A,  top) . This finding is similar to our previous results obtained using α1β2 receptors and F6. 19 However, when receptors were activated by 1 μM GABA, F6 enhanced peak currents (Fig. 1A, bottom) . The results of a series of experiments using a range of GABA concentrations are summarized in Figure 1B . The effects of 1 MAC pred F6 ranged from enhancement of the responses to low concentrations of GABA (+96 ± 11% at 1 μM, P = 0.003) to inhibition at high concentrations (−24 ± 4%, versus control at 1 mM, P < 0.0001).
Effects on α5β3γ2L Receptors
We also examined the effects of F6 on responses of heterotrimeric α5β3γ2L receptors activated by low and high concentrations of GABA. An example of 1 such experiment is shown in Figure 2 . In contrast to its effects on heterodimeric receptors, F6 did not block responses to 1 mM GABA ( Fig. 2A, top traces ). Responses to low concentrations of GABA were, however, still markedly enhanced by F6 ( Fig. 2A, bottom trace) . A summary of the results obtained with α5β3γ2L receptors is shown in Figure 2B 
Kinetic Analysis
To help define the possible kinetic mechanisms by which F6 enhanced subsaturating responses of heterotrimeric channels, we analyzed deactivation trajectories for α5β3γ2L receptors triggered to open by 20-ms pulses of 1 mM GABA in the absence and the continuous presence of F6 (Fig. 2C) . Unlike conventional anesthetics, which typically prolong current decay, 2 F6 failed to alter deactivation (τ wt F6/control = 105 ± 5.2%, n = 14, P = 0.70). This observation indicates that the molecular mechanisms by which F6 and conventional anesthetics modulate GABA A Rs differ, and it places limits on the possible kinetic mechanisms by which F6 might enhance low-concentration responses (discussion below contains more detail).
Effects on Mutant Receptors
To test whether the enhancement of responses to low GABA concentrations by F6 shares structural requirements with other volatile drugs, we tested whether a mutation at the N265 position of the β3 subunit that interferes with positive receptor modulation by enflurane 8, 9 also influences modulation by F6. In order to compare equi-effective concentrations in the wild-type and mutant receptors, we first established a GABA concentration-response relationship for α5β3(N265M)γ2L subunit-containing GABA A Rs (Fig. 3A) . The mutant heterotrimeric receptor displayed a nearly 2-fold higher EC 50 for GABA compared with wild-type receptors (compare with Fig. 2B ), consistent with previous results using α2β3γ2 receptors. 8 An example of the effect of F6 on these mutant receptors is shown in Figure 3B . Similar to its effect on wild-type receptors, F6 had no effect on the peak amplitude of responses triggered by 1 mM GABA (Fig. 3B , upper traces). Most remarkably, however, F6 failed to enhance the responses of mutant receptors to 3 μM GABA (~EC 20 ) (Fig. 3B, bottom traces) . On average, whereas F6 enhanced EC 20 responses from wild-type receptors by 310 ± 215% (1 μM GABA, P = 0.0015, n = 5), mutant receptors may have been blocked by 21.7 ± 8.6% (3 μM GABA, P = 0.0095, n = 5). These data indicate that the N265 position is critical for the enhancing effect of F6 on GABA-activated receptors, as it is for the volatile anesthetic enflurane acting on α2β3γ2 GABA A Rs. 8 
Concentration Dependence of Modulation
Using slower (~30 ms) solution exchange methods, we tested the concentration dependence of F6 modulation of α5β3γ2L and α5β3(N265M)γ2L receptors. An example of 1 such experiment is shown in Figure 4A . At concentrations ranging from 4 to 16 μM, F6 enhanced responses to 1 μM GABA in a concentration-dependent manner for α5β3γ2L receptors, but there was little or no enhancement of α5β3(N265M)γ2L receptors. A summary of effects at different concentrations is presented in Figure 4B . On average, responses of wild-type receptors to 1 μM GABA in the presence of 8 μM F6 (the EC 50 concentration for suppressing fear conditioning to context) 4 were 2.7 ± 0.47 times larger than in the absence of F6 (P = 0.0003, n = 5), but mutant receptor responses were not significantly larger (1.3 ± 0.12 times, P = 0.02, n = 5). This strong enhancement of low GABA concentration responses by a low concentration of F6 is consistent with a role for α5-containing receptors that mediate tonic or slow phasic inhibition triggered by ambient GABA or spillover from nearby synapses 20 in memory impairment.
Effects on α1β2γ2L Receptors
We showed previously that F6 neither blocks nor alters deactivation of α1β2γ2s receptors activated by brief pulses of a high concentration of GABA, 19 similar to our present results with α5β3γ2L receptors. However, in our previous study, we did not test responses to subsaturating GABA concentrations. To test whether F6 enhances responses of α1β2γ2L receptors activated by a low concentration of GABA, we measured peak currents triggered by 1 μM GABA in the absence and presence of F6. At concentrations up to 16 μM, F6 failed to enhance the responses of α1β2γ2L receptors (8 μM 90% ± 7%, P = 0.20; 16 μM 99% ± 10%, P = 0.99; n = 5 for both). Thus, enhancement of low-concentration GABA responses by F6 is subunit-specific.
DISCUSSION
We have combined 2 experimental strategies recently introduced to anesthetic research: F6, which is the best studied representative of the nonimmobilizer class of drugs, and the N265M point mutation of the GABA A R β3 subunit, which conveys resistance to both IV and inhaled anesthetic modulation in vitro 8 and in vivo. 21 Together, they have allowed us to address the mechanism of enhancement of GABA A receptors to low concentrations of agonist by the nonimmobilizer F6.
The γ-Subunit Determines Sensitivity to Block
We found that the presence of the γ-subunit renders receptors incorporating α5 and β3 subunits insensitive to block by F6. That is, whereas heterodimeric α5β3 receptors activated by (near)-saturating concentrations of GABA were blocked by ~25% in the presence of 16 μM F6, no block of α5β3γ2 receptors was measurable. We reported previously that the γ-subunit exerts a similar effect when combined with α1β2 receptors. 19 Therefore, this finding supports an emerging general principle that the γ-subunit plays an important modulatory role for the interaction of GABA A Rs with anesthetics and anestheticlike compounds. 19, [22] [23] [24] F6 Enhances Responses to GABA Similar to conventional inhaled anesthetics, F6 enhanced both α5β3 and α5β3γ2L receptors activated by low concentrations of GABA. This effect of F6 was seen at concentrations of F6 as low as 4 μM, or one-quarter of MAC pred . Like conventional anesthetics, which cause amnesia at concentrations that are substantially lower than those required to prevent movement, low concentrations of F6 also impair the formation of long-term memories. 4 Previously, enhancement was not observed for α1β2γ2S receptors expressed in Xenopus oocytes. 25 We replicated this finding for α1β2γ2L receptors, demonstrating that the lack of effect of F6 on α1β2γ2 receptors cannot be attributed to the expression system (mammalian human embryonic kidney 293 cells versus frog oocytes), other technical factors (e.g., difficulties in preparing aqueous solutions of F6 26 or slow solution exchange around oocytes), or the specific splice variant of the γ-subunit that was used (γ2S vs γ2L). Rather, this finding demonstrates that positive modulation by F6 depends on the specific α and/or β subunits incorporated into the GABA A R.
Common Molecular Sites for Nonimmobilizers and Anesthetics?
Originally, a region of 45 amino acids within the TM2 and TM3 domains was identified as being critical for enhancement by enflurane and ethanol of responses to an EC 10 concentration of GABA. 5 Subsequently, single-amino-acid mutations in TM2 (N265M) and TM3 (M286W) of the β3 subunit were shown to result in a partial loss of sensitivity of expressed α2β3γ2 receptors to enhancement by etomidate and enflurane. 8 The critical residues were proposed to line an intrasubunit cavity that can accommodate either an anesthetic molecule or an amino acid side chain. 27 More recent results combining photoaffinity labeling with crystallography and structural modeling indicate that the N265 residue lies at the interface between adjacent α and β subunits. 28, 29 In either case, our present finding that the β3(N265M) mutation also renders α5β3γ2L receptors insensitive to enhancement by F6 demonstrates that this structural requirement for the enhancement of α5β3-subunit-containing GABA A Rs applies to the nonimmobilizer F6 as well.
Because we did not test other subunit combinations, such as α5 combined with the β2 rather than β3 subunit or α1 combined with β3 rather than β2, we cannot know with certainty which specific subunit or combination is critical to F6 sensitivity. Both β2and β3-containing receptors are sensitive to etomidate, and both incorporate an asparagine residue at the 265 position, so both may also be sensitive to F6 when combined with the α5 subunit. Indeed, specific residues in α subunits, such as α1-S270, are key determinants of sensitivity to isoflurane and other inhaled drugs. 27, 30 If the identity of the α subunit is the critical factor for F6 sensitivity, the key differences must lie outside of the M2 membrane-spanning helix where the S270 residue is located because the amino acid sequences of α1 and α5 subunits are identical in this region. Therefore, other domains of the α subunits or β subunits, or combinations thereof, must be the determining factors for F6 sensitivity.
Kinetic Mechanisms of Potentiation
Based on the currently available kinetic models of GABA A R function, the spectrum of macroscopic effects that we observed, enhancement of subsaturating responses with no effect on deactivation time course, limits the kinetic transitions on which F6 could be acting to produce these effects.
Two agonist-binding sites are present at the 2 α-β subunit interfaces, 31 and both must be occupied for receptors to reach high levels of activation. 32 Drugs that further stabilize the long-lived open state not only enhance responses to low concentrations of GABA but also lead to a slowing of receptor deactivation after agonist removal. 2 Therefore, this common mode of anesthetic action appears not to apply directly to F6. However, F6 could be acting through a slightly different but related mechanism by stabilizing the short-lived open state produced by a receptor that is bound to a single molecule of GABA. Such an effect would enhance lowconcentration responses without prolonging deactivation to the same extent as stabilization of the long-lived open state. Another possibility is that F6 might accelerate an agonist-binding step rather than directly altering channel gating. However, our finding that the N265M mutation in the TM region (near the channel gate but distant from the extracellular GABA binding site) influences F6 sensitivity, together with other studies showing that drugs that are thought to bind in this region increase the efficacy of partial agonists, 33, 34 suggests that anesthetics, and by analogy nonimmobilizers, alter gating transitions rather than agonist binding. Detailed studies of single-channel characteristics will be necessary to test these possibilities and to better define the similarities and differences in molecular actions of conventional anesthetics versus F6.
Physiologic Implications
Pharmacologic and physiologic evidence indicates that the α5β3γ2L subunit combination is the most prevalent hippocampal form of receptors incorporating the α5 subunit. [35] [36] [37] These subunits are highly co-localized in the dendritic layers (stratum radiatum and stratum oriens) of the CA1 and CA3 fields of the hippocampus. 38, 39 Compared with α1 subunits, α5 subunit-containing receptors display high GABA affinity and reduced desensitization. 40, 41 These properties enable them to mediate tonic inhibition as well as slow phasic inhibition in the dendrites, 42 a spillover-mediated response that is produced by a subsaturating concentration of transmitter. 43, 44 Thus, F6 modulation of either tonic or slow dendritic inhibition may underlie its ability to impair hippocampusdependent memory. In this regard, F6 might further share cellular-and network-level mechanisms of action with IV and inhaled general anesthetics, which are also proposed to impair memory via modulation of receptors that incorporate α5 14,41 and β3 11 subunits. E
